| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7979da6ca817674f0dd32237853b40c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_577821cf81fda3e1088e6ed08bcd136b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7343a2d9b29e818a63bf3a239a52718a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4816dfa73f0e1193b60be25585b21af |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 |
| filingDate |
2004-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d3a9c6228d0dc1149051d2a95f9a85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a41a9e771d69b2edc79a9baced6e4a81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22ac52bfa24682e7c600787512aef4c1 |
| publicationDate |
2005-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005033694-A2 |
| titleOfInvention |
Novel antisense oligomers and use thereof |
| abstract |
The invention relates to the use of a novel type of antisense oligomers for use in the in vitro or in vivo inhibition of gene expression of a target gene. These oligomers, called exon-bridging oligomers are complementary to those parts of a spliced mRNA which are derived from two adjacent exons in the primary RNA transcript, and are called exon-bridging antisense oligomers. These oligomers have no complimentarity to genomic DNA. These oligomers can be used to performs antisense inhibition with less aspecific binding to genomic DNA. The exon-bridging oligomers are suitable for inhibiting Interleukin1 type I Receptor in, for instance, chondrocytes, and are suitable for the prevention or treatment of osteoarthritis. |
| priorityDate |
2003-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |